Safety of intravitreal ziv-aflibercept in choroido-retinal vascular diseases: A randomised double-blind intervention study
Sign Up to like & getrecommendations! Published in 2019 at "PLoS ONE"
DOI: 10.1371/journal.pone.0223944
Abstract: Aim To evaluate the safety of 1.25mg and 2mg intravitreal ziv-aflibercept (IVZ) in Ghanaian eyes with choroido-retinal vascular diseases. Design Prospective, randomised, double blind, interventional study. Methods Twenty patients with centre involving macular oedema in… read more here.
Keywords: retinal vascular; intravitreal ziv; ziv aflibercept; safety ... See more keywords
Effectiveness of the Use of Three-Dose Intravitreal Ziv-Aflibercept in the Management of Diabetic Macular Edema in a Real-Life Setting.
Sign Up to like & getrecommendations! Published in 2023 at "Clinical ophthalmology"
DOI: 10.2147/opth.s398359
Abstract: Purpose It has been reported that intravitreal Ziv-aflibercept is a safe and effective drug for the treatment of diabetes macular edema (DME). The objective of this study was to evaluate in a real-life setting, the… read more here.
Keywords: intravitreal ziv; real life; ziv aflibercept; macular edema ... See more keywords
Intravitreal Ziv‐Aflibercept: Clinical Effects and Economic Impact
Sign Up to like & getrecommendations! Published in 2017 at "Asia-Pacific Journal of Ophthalmology"
DOI: 10.22608/apo.2017263
Abstract: Abstract: During the past decade, drugs that inhibit the actions of vascular endothelial growth factor (VEGF) have become standard‐of‐care treatment for a variety of chorioretinal vascular conditions. The off‐label, intravitreal use of ziv‐aflibercept (Zaltrap) has… read more here.
Keywords: intravitreal ziv; ziv aflibercept; clinical effects; ziv ... See more keywords